One more bispecific, humanized IgG1 antibody that may be below investigation is zenocutuzumab (MCLA-128), which acts by using two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells through ADCC. MCLA-128 functions by using a ‘dock and block’ mechanism whereby just one arm in the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/